Cargando…
Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines
BACKGROUND: Gastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of cancer death worldwide. The molecular mechanisms of action for anti-HER-family drugs in gastric cancer cells are incompletely understood. We compared the molecular effects of trastuzumab and the o...
Autores principales: | Ebert, Karolin, Zwingenberger, Gwen, Barbaria, Elena, Keller, Simone, Heck, Corinna, Arnold, Rouven, Hollerieth, Vanessa, Mattes, Julian, Geffers, Robert, Raimúndez, Elba, Hasenauer, Jan, Luber, Birgit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594334/ https://www.ncbi.nlm.nih.gov/pubmed/33115415 http://dx.doi.org/10.1186/s12885-020-07540-7 |
Ejemplares similares
-
Correction to: Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines
por: Ebert, Karolin, et al.
Publicado: (2020) -
Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies—the role of HAS2, SHB and HBEGF
por: Ebert, Karolin, et al.
Publicado: (2022) -
Model-based analysis of response and resistance factors of cetuximab treatment in gastric cancer cell lines
por: Raimúndez, Elba, et al.
Publicado: (2020) -
Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines
por: Keller, Simone, et al.
Publicado: (2018) -
MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells
por: Ebert, Karolin, et al.
Publicado: (2019)